Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)
7.78
-0.33 (-4.07%)
Jun 10, 2026, 3:00 PM CST
SHA:600222 Revenue
Henan Taloph Pharmaceutical Stock Co.,Ltd had revenue of 350.23M CNY in the quarter ending March 31, 2026, with 8.34% growth. This brings the company's revenue in the last twelve months to 1.78B, up 1.09% year-over-year. In the year 2025, Henan Taloph Pharmaceutical Stock Co.,Ltd had annual revenue of 1.76B, down -9.46%.
Revenue (ttm)
1.78B
Revenue Growth
+1.09%
P/S Ratio
2.41
Revenue / Employee
856.40K
Employees
2,084
Market Cap
4.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.76B | -183.63M | -9.46% |
| Dec 31, 2024 | 1.94B | -128.49M | -6.21% |
| Dec 31, 2023 | 2.07B | 109.21M | 5.57% |
| Dec 31, 2022 | 1.96B | 356.18M | 22.20% |
| Dec 31, 2021 | 1.60B | 187.42M | 13.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 25.24B |
| HPGC Renmintongtai Pharmaceutical | 10.54B |
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.59B |
| Jiangsu Lianhuan Pharmaceutical | 2.89B |
| Luoxin Pharmaceuticals Group Stock | 2.37B |
| Beijing Beilu Pharmaceutical | 1.24B |
| Jiangsu Jibeier Pharmaceutical | 990.68M |
| ChengDu ShengNuo Biotec | 801.40M |